ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2018
Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03783091 (A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock
Who cites it
7 citing papers in PubMed, 28 citations in OpenAlex.
- Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series.JHLT open · 2025Article
- Angiotensin II as a Vasopressor for Perioperative Hypotension in Solid Organ Transplant.Biomedicines · 2024Review
- Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial.BMJ open · 2023Article
- Norepinephrine boluses for the prevention of post-reperfusion syndrome in living donor liver transplantation: A prospective, open-label, single-arm feasibility trial.Indian journal of anaesthesia · 2023Article
- Hydroxocobalamin Administration After Inhalation Injury Is Not Associated With Mesenteric Ischemia.Annals of burns and fire disasters · 2021Article
- Vasoplegia after cardiopulmonary bypass: A narrative review of pathophysiology and emerging targeted therapies.SAGE open medicine · 2020Review
- High-dose hydroxocobalamin in end-stage liver disease and liver transplantation.Drugs & therapy perspectives : for rational drug selection and use · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
A 66-year-old man with cryptogenic cirrhosis secondary to nonalcoholic steatohepatitis presented for orthotopic liver transplantation. Following organ reperfusion, the patient developed vasoplegic syndrome, with arterial blood pressures of approximately 60-70/30-40 mm Hg (mean arterial pressure [MAP] <45 mm Hg) for >90 minutes. He required high-dose norepinephrine and vasopressin infusions, as well as i.v. bolus doses of norepinephrine and vasopressin to reach a goal MAP> 60 mm Hg. There was minimal response to a 2 mg/kg i.v. bolus of methylene blue. Following the administration of 5 g of i.v.hydroxocobalamin, the patient had a profound improvement in arterial blood pressure, with subsequent discontinuation of the vasopressin infusion and rapid reduction of norepinephrine infusion from 20 to 2 μg/min. While there have been several reports of the efficacy of hydroxocobalamin for vasoplegia after cardiopulmonary bypass, there have been only limited cases of hydroxocobalamin used in liver transplantation, and none with high-dose administration. We present a case of vasoplegic syndrome during liver transplantation that was refractory to high-dose vasopressors and methylene blue but responsive to high-dose i.v. hydroxocobalamin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.